Trial
NCT04385524
Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection
UnknownWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Louisville
Collaborators
Dynavax Technologies Corporation
Condition
Hepatitis B Virus
Intervention
Adjuvanted Hepatitis B Vaccine
Why stopped
We decided to close this study. We are unable to perform this study due to the current pandemic.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-30